Literature DB >> 12003413

Corticosteroids in Crohn's disease.

Yu-Xiao Yang1, Gary R Lichtenstein.   

Abstract

Crohn's disease is a lifelong illness characterized by chronic recurrent flares. The precise etiology of Crohn's disease is unknown. However, it appears to involve an enhanced systemic immune response and intensified local intestinal mucosal inflammatory activity, mediated through various inflammatory cells and an array of proinflammatory cytokines. Corticosteroids have been the mainstay of treatment of Crohn's disease. The controlled trials of the National Cooperative Crohn's Disease Study and the European Cooperative Crohn's Disease Study established that corticosteroids were effective for the induction of remission in Crohn's disease for the duration of the studies (6-17 wk). However, corticosteroids have not been shown to have an impact on the maintenance of long term remission in patients with Crohn's disease. In addition, they are associated with a high potential for dependence and serious toxic side effects. Alternative classes of medical therapy for Crohn's disease, including modified corticosteroids and a group of new biological therapies, have proven to be efficacious in the management of active and/or quiescent Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003413     DOI: 10.1111/j.1572-0241.2002.05596.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  25 in total

1.  Acute activation of NHE3 by dexamethasone correlates with activation of SGK1 and requires a functional glucocorticoid receptor.

Authors:  Dongsheng Wang; Huanchun Zhang; Florian Lang; C Chris Yun
Journal:  Am J Physiol Cell Physiol       Date:  2006-09-13       Impact factor: 4.249

Review 2.  Steroid use in Crohn's disease.

Authors:  Stephan R Vavricka; Alain M Schoepfer; Michael Scharl; Gerhard Rogler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

3.  The activity of organic anion transporter-3: Role of dexamethasone.

Authors:  Haoxun Wang; Chenchang Liu; Guofeng You
Journal:  J Pharmacol Sci       Date:  2018-02-02       Impact factor: 3.337

Review 4.  Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

Authors:  John K MacDonald; Tran M Nguyen; Reena Khanna; Antje Timmer
Journal:  Cochrane Database Syst Rev       Date:  2016-11-25

5.  Inflammatory bowel disease in children: psychological and psychiatric issues.

Authors:  Parikshit Deshmukh; Gaurav Kulkarni; Jeanne Lackamp
Journal:  Curr Psychiatry Rep       Date:  2010-06       Impact factor: 5.285

Review 6.  PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Man Cai Wang; Ling Yi Zhang; Wei Han; Yuan Shao; Mo Chen; Rui Ni; Gen Nian Wang; Feng Xian Wei; Ya Wu Zhang; Xiao Dong Xu; You Cheng Zhang
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 7.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

8.  Successful treatment of asymptomatic or clinically terminal bovine Mycobacterium avium subspecies paratuberculosis infection (Johne's disease) with the bacterium Dietzia used as a probiotic alone or in combination with dexamethasone: Adaption to chronic human diarrheal diseases.

Authors:  Robert E Click
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

9.  Medical treatment of ulcerative colitis.

Authors:  Uma Mahadevan
Journal:  Clin Colon Rectal Surg       Date:  2004-02

Review 10.  Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.

Authors:  Staffan Edsbäcker; Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.